MedTrace Logo

Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

NCT02769637 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2018-06-27

No results posted yet for this study

Summary

Mucus in the airways of patients with CF represents an area for bacteria proliferation, microbial infection and inflammation. Similar to the lung, the esophagus provides an environment for bacterial to grow. The overall goal of this proposal is to characterize the esophageal microbiota of children with CF that are treated or untreated with acid blockade medication and to measure its possible impact on respiratory disease to develop novel treatment strategies.

Conditions

Interventions

DRUG

PPI treatment

PPI treatment or no PPI treatment

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Sophie Fillon, PhD · University of Colorado, Denver

Eligibility

Min Age
10 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2018-01-18
Completion
2018-01-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02769637 on ClinicalTrials.gov